Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance

Molecular Cancer Research

Volumn 12, Issue 4, 2014, Pages 539-549

  Zou, June X ^a,b   Duan, Zhijian ^a,b   Wang, Junjian ^a,b   Sokolov, Alex ^a,b   Xu, Jianzhen ^c   Chen, Christopher Z ^a,b   Li, Jian Jian ^a   Chen, Hong Wu ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HENAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AAA NUCLEAR COREGULATOR CANCER ASSOCIATED PROTEIN; ESTROGEN; HISTONE H3; HISTONE H3K4; KINESIN; MIXED LINEAGE LEUKEMIA PROTEIN; PEPTIDES AND PROTEINS; TAMOXIFEN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ANTIESTROGEN; ATAD2 PROTEIN, HUMAN; DNA BINDING PROTEIN; ESTRADIOL; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; HISTONE METHYLATION; HUMAN; HUMAN CELL; KIF10 GENE; KIF11 GENE; KIF15 GENE; KIF18A18B GENE; KIF1A GENE; KIF1C GENE; KIF20A20B GENE; KIF21 GENE; KIF23 GENE; KIF24 GENE; KIF25 GENE; KIF4A4B GENE; KIF5A5B GENE; KIF7 GENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL GROWTH; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

ADENOSINE TRIPHOSPHATASES; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KINESIN; MCF-7 CELLS; TAMOXIFEN; TRANSFECTION; UP-REGULATION;

EID: 84925546200     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0459     Document Type: Article

References (49)

1. Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer 2012;12: 527-39.
2. Xu Y, Takeda S, Nakata T, Noda Y, Tanaka Y, Hirokawa N. Role of KIFC3 motor protein in Golgi positioning and integration. J Cell Biol 2002;158:293-303.
3. Semiz S, Park JG, Nicoloro SM, Furcinitti P, Zhang C, Chawla A, et al. Conventional kinesin KIF5B mediates insulin-stimulated GLUT4 movements on microtubules. EMBO J 2003;22:2387-99.
4. Wiesner C, Faix J, Himmel M, Bentzien F, Linder S. KIF5B and KIF3A/KIF3B kinesins drive MT1-MMP surface exposure, CD44 shedding, and extracellular matrix degradation in primary macrophages. Blood 2010;116:1559-69.
5. Cheung HO, Zhang X, Ribeiro A, Mo R, Makino S, Puviindran V, et al. The kinesin protein Kif7 is a critical regulator of Gli transcription factors in mammalian hedgehog signaling. Sci Signal 2009;2:ra29.
6. Scholey JM. Kinesin-2: a family of heterotrimeric and homodimeric motors with diverse intracellular transport functions. Annu Rev Cell Dev Biol 2013;29:443-69.
7. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009;15:3654-62.
8. De S, Cipriano R, Jackson MW, Stark GR. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 2009;69:8035-42.
9. Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, et al. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat 2012;131: 849-58.
10. Zhang C, Zhu C, Chen H, Li L, Guo L, Jiang W, et al. Kif18A is involved in human breast carcinogenesis. Carcinogenesis 2010;31:1676-84.
11. Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, et al. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triplenegative breast cancer. Clin Cancer Res 2013;19:2061-70.
12. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144:4562-74.
13. Bourdeau V, Deschenes J, Laperriere D, Aid M, White JH, Mader S. Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Res 2008;36:76-93.
14. Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, Siepel AC, et al. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. Mol Cell Biol 2007;27:5090-104.
15. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006;38:1289-97.
16. Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A 2013;110:E1490-9.
17. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 2012;132:61-73.
18. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 2011;17:2024-34.
19. Won Jeong K, Chodankar R, Purcell DJ, Bittencourt D, Stallcup MR. Gene-specific patterns of coregulator requirements by estrogen receptor-alpha in breast cancer cells. Mol Endocrinol 2012;26: 955-66.
20. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. Regulation of hormoneinduced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 1999;98:675-86.
21. Stender JD, Kim K, Charn TH, Komm B, Chang KC, Kraus WL, et al. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 2010;30: 3943-55.
22. Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, et al. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 2011;145:622-34.
23. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogenregulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A 2007;104:18067-72.
24. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 2010;29:5171-81.
25. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 2009;69:8491-8.
26. Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010;70:9402-12.
27. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol 2010;30: 5260-72.
28. Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res 2009;69: 3339-46.
29. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012;32:3121-31.
30. Caslini C, Connelly JA, Serna A, Broccoli D, Hess JL. MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol 2009;29:4519-26.
31. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
32. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010;123:725-31.
33. Theisen U, Straube E, Straube A. Directional persistence of migrating cells requires Kif1C-mediated stabilization of trailing adhesions. Dev Cell 2012;23:1153-66.
34. Arteaga CL, Koli KM, Dugger TC, Clarke R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 1999;91: 46-53.
35. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-32.
36. Karmakar S, Foster EA, Blackmore JK, Smith CL. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogenindependent, tamoxifen-resistant breast cancer cell line. Endocr Relat Cancer 2011;18:113-27.
37. Riggs KA, Wickramasinghe NS, Cochrum RK, Watts MB, Klinge CM. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Cancer Res 2006;66:10188-98.
38. Kobayashi T, Tsang WY, Li J, Lane W, Dynlacht BD. Centriolar kinesin Kif24 interacts with CP110 to remodel microtubules and regulate ciliogenesis. Cell 2011;145:914-25.
39. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
40. Li ZJ, Nieuwenhuis E, Nien W, Zhang X, Zhang J, Puviindran V, et al. Kif7 regulates Gli2 through Sufu-dependent and -independent functions during skin development and tumorigenesis. Development 2012;139:4152-61.
41. Hao H, d'Alincourt-Salazar M, Kelley KM, Shatnawi A, Mukherjee S, Shah YM, et al. Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen. Oncogene 2007;26:7872-84.
42. Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol Cell Biol 2009;29:1749-59.
43. Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer 2011;104:300-7.
44. Takahashi S, Fusaki N, Ohta S, Iwahori Y, Iizuka Y, Inagawa K, et al. Downregulation of KIF23 suppresses glioma proliferation. J Neurooncol 2012;106:519-29.
45. Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishimura H, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007;13:6624-31.
46. Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, et al. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate 2013;73:455-66.
47. Lin JJ, Lehmann LW, Bonora G, Sridharan R, Vashisht AA, Tran N, et al. Mediator coordinates PIC assembly with recruitment of CHD1. Genes Dev 2011;25:2198-209.
48. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
49. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.